Fatty Liver Disease has become a public health concern among the people of Bangalore. The condition can occur with/without the consumption of alcohol and progress to NAFLD (NonAlcoholic Fatty Liver Disease). The severe for NAFLD is NASH (Non-Alcoholic Steatohepatitis). When NASH is left untreated, it leads from fibrosis to cirrhosis. Currently, there are only 02 approved drugs, Saroglitazar, (approved by DCGI, India) and Rezdiffra (The FDA, USA). Many pharmaceutical companies are conducting clinical trials for NASH to bring novel therapies. However, patient recruitment has always been a challenge for NASH clinical trials. The main objective is to investigate how social media platforms can be utilized to create awareness about NASH and Clinical trials. We want to understand what are the attitudes and preferences of people towards social media platforms, NASH & Clinicals. The research has utilized a mixed approach (Interviews/Surveys) to analyze the impact of social media platforms. Social media are an unavoidable platform and primary source of information for more than 5 billion people across the globe. The research findings reveal that social media platforms are the primary source of health-related information. The top three platforms are YouTube, Instagram, and WhatsApp utilized by the people of Bangalore to understand complex health information and share the information on personal networks i,e friends & family. The people are aware of NASH, its risk factors, and Clinical trials however they lack detailed knowledge about the process. Though they are anxious about the fear of side effects but still are motivated to participate in clinical trials due to personal health benefits. Through a patientcentric approach, the CRPs suggested that transparent communication can be the key to addressing these fears and concerns. This research has on focused on how social media platforms can be an effective method to educate the public to overcome the patient recruitment challenges for NASH Clinical trials.